PMID: 8938526Oct 1, 1996Paper

Minimal residual disease: detection, clinical relevance, and treatment strategies

Journal of Hematotherapy
A DwengerR Mertelsmann

Abstract

Improvement of established treatment strategies for cancer has resulted in increased survival times for patients with malignancies. However, success of surgery, chemotherapy, and radiotherapy is limited, as even combined and repeated therapy regimens and high-dose chemotherapy can only reduce tumor burden by several logarithmic steps and are not able to completely eradicate all neoplastic cells. If clinically complete remission is achieved--that is, if no sign of the tumor is detectable by standard diagnostic procedures, remaining minimal residual disease (MRD) can eventually give rise to clinically manifest relapse. More sensitive methods are, therefore, necessary to detect single tumor cells for exact staging, to assess the metastatic potential of an individual tumor, to evaluate the sensitivity to prior therapy, and to detect MRD-positive patients with remaining malignant cells who are at higher risk for relapse. Novel treatment approaches must be created to eradicate minimal residual disease after conventional therapy.

References

Oct 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I J DielG Bastert
Jul 9, 1992·International Journal of Cancer. Journal International Du Cancer·A DouvdevaniR N Apte
Oct 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J CoteM P Osborne
Oct 1, 1990·The Journal of Experimental Medicine·B GansbacherE Gilboa
Jul 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·M YamadaG Rovera
Jun 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·A F LoBuglioM B Khazaeli
Jul 18, 1995·Proceedings of the National Academy of Sciences of the United States of America·M MackP Kufer
Apr 1, 1995·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·R MertelsmannH Veelken
Jun 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·S BaskarL H Glimcher
Sep 1, 1993·Journal of the National Cancer Institute·K PantelG Riethmüller
Oct 21, 1993·The New England Journal of Medicine·O W PressB Porter
May 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J E HardinghamB M Dale
Jan 17, 1995·Proceedings of the National Academy of Sciences of the United States of America·H J GrossD Recktenwald
Aug 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A C LambrechtsM B van't Veer
Sep 13, 1994·Proceedings of the National Academy of Sciences of the United States of America·Y LiuG A Cortopassi
Feb 1, 1994·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·M J VisserenC J Melief
Apr 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P W JohnsonT A Lister

❮ Previous
Next ❯

Citations

Mar 1, 2006·Photodiagnosis and Photodynamic Therapy·Herbert C Wolfsen, Lois L Hemminger
Dec 18, 2001·Seminars in Surgical Oncology·P Kienle, M Koch

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.